As of 2025-12-30, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -3.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 157.01 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -50.55 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.5x - 6.9x | 5.9x |
| Forward P/E multiples | 7.3x - 16.1x | 8.9x |
| Fair Price | (4.14) - (3.96) | (4.21) |
| Upside | -367.2% - -355.8% | -372.1% |
| Date | EV/EBITDA |
| 2025-12-29 | -3.10 |
| 2025-12-24 | -3.11 |
| 2025-12-23 | -3.06 |
| 2025-12-22 | -3.13 |
| 2025-12-19 | -3.08 |
| 2025-12-18 | -3.11 |
| 2025-12-17 | -3.14 |
| 2025-12-16 | -3.22 |
| 2025-12-15 | -3.24 |
| 2025-12-12 | -3.26 |
| 2025-12-11 | -3.32 |
| 2025-12-10 | -3.28 |
| 2025-12-09 | -3.28 |
| 2025-12-08 | -3.31 |
| 2025-12-05 | -3.33 |
| 2025-12-04 | -3.35 |
| 2025-12-03 | -3.40 |
| 2025-12-02 | -3.45 |
| 2025-12-01 | -3.43 |
| 2025-11-28 | -3.47 |
| 2025-11-27 | -3.40 |
| 2025-11-26 | -3.32 |
| 2025-11-25 | -3.33 |
| 2025-11-24 | -3.28 |
| 2025-11-21 | -3.24 |
| 2025-11-20 | -3.21 |
| 2025-11-19 | -3.18 |
| 2025-11-18 | -3.11 |
| 2025-11-17 | -3.14 |
| 2025-11-14 | -3.18 |
| 2025-11-13 | -3.21 |
| 2025-11-12 | -3.31 |
| 2025-11-11 | -3.40 |
| 2025-11-10 | -3.69 |
| 2025-11-07 | -3.06 |
| 2025-11-06 | -3.03 |
| 2025-11-05 | -3.14 |
| 2025-11-04 | -3.21 |
| 2025-11-03 | -3.28 |
| 2025-10-31 | -3.33 |
| 2025-10-30 | -3.38 |
| 2025-10-29 | -3.44 |
| 2025-10-28 | -3.36 |
| 2025-10-27 | -3.73 |
| 2025-10-24 | -3.66 |
| 2025-10-23 | -3.60 |
| 2025-10-22 | -3.58 |
| 2025-10-21 | -3.57 |
| 2025-10-20 | -3.55 |
| 2025-10-17 | -3.63 |